Smoking, haemostatic factors, and cardiovascular risk

Current Pharmaceutical Design

Volumn 13, Issue 16, 2007, Pages 1661-1667

  Leone, Aurelio ^a,b,c,d  

^a Royal Society of Health   (United Kingdom)

^b Massa Hosp   (Italy)

^c Carrara City Hospital   (Italy)

^d NONE   (Italy)

Author keywords

Cardiovascular risk; Coagulation fibrinolysis; Smoking

Indexed keywords

FIBRIN; FIBRINOGEN; ORAL CONTRACEPTIVE AGENT; TOBACCO SMOKE;

ATHEROSCLEROSIS; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CORONARY ARTERY THROMBOSIS; ENDOTHELIUM; ENDOTHELIUM LESION; FIBRINOLYSIS; GENDER; HEMOSTASIS; HUMAN; INCIDENCE; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBUS;

ATHEROSCLEROSIS; BLOOD COAGULATION; CARDIOVASCULAR DISEASES; CONTRACEPTIVES, ORAL; ENDOTHELIUM, VASCULAR; FEMALE; FIBRINOLYSIS; HUMANS; MALE; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; SMOKING; THROMBOSIS;

EID: 34250798534     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780831347     Document Type: Review

References (115)

1. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB, Kannel WB, Schatzkin A. Risk factor analysis. Progr Cardiov Dis 1983; 26: 309-32.
2. Fibrinogen and risk of cardiovascular disease: The Framingham Study. JAMA 1987; 258: 1183-6.
3. Ridker PM, Hennekens CH. Haemostatic risk factors for coronary heart disease. Circulation 1991; 83: 1098-100.
4. Fowkes FGR. Aetiology of peripheral atherosclerosis. Smoking seems especially important. Br Med J 1989; 298: 405-6.
5. Trap-Jensen J. Effects of smoking on the heart and peripheral circulation. Am Heart J 1988; 115: 263-6.
6. Folts JD, Bonebrake FC. The effects of cigarette smoke and nicotine on platelet thrombus formation in stenosed dog coronary arteries; inhibition with phentolamine. Circulation 1982; 65: 465-9.
7. Meade T, Imeson J, Sterling Y. Effects of changes in smoking and other characteristics in clotting factors and the risk of ischaemic heart disease Lancet 1987; ii: 986-8.
8. FitzGerald GA, Smith B, Pederson AK, Brash AR. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 1984; 310: 1065-8.
9. Lassila R, Laustiola KE. Cigarette smoking and peripheral arterial occlusive disease-evidence for adrenergic connections. J Smoking-Related Dis 1992; 3: 217-23.
10. Leone A. Cardiovascular damage from smoking: A fact or belief? Int J Cardiol 1993; 38: 113-7.
11. Leone A. Cigarette smoking and health of the heart. J Roy Soc Health 1995; 1115: 354-5.
12. Reid DD, Hamilton PJS, McCartney P, Rose G. Smoking and other risk factors in coronary heart disease in British civil servants. Lancet 1976; ii: 979-84.
13. Leone A. Relationship between cigarette smoking and other coronary risk factors in atherosclerosis: Risk of cardiovascular disease and preventive measures. Curr Pharm Design 2003; 9(29): 2417-23.
14. Sherman CB. Health effects of cigarette smoking. Clin Chest Med 1991; 12(4): 643-58.
15. Leone A. The heart: A target organ for cigarette smoking. J Smoking Related Dis 1992; 3: 197-201.
16. Hammond EC, Garfinkel L. Coronary heart disease, stroke, and aortic aneurysm. Arch Environ Health 1969; 19: 167-82.
17. Aronow WS. Effect of passive smoking on angina pectoris. N Engl J Med 1978; 299: 21-4.
18. Leone A, Bertanelli F, Mori L, Fabiano P, Bertoncini G. Ventricular arrhythmias by passive smoking in patients with pre-existing myocardial infarction. J Am Coll Cardiol 1992; 3: 256 A. Abstract.
19. Wilhelmsson C, Vedin JA, Elmfeldt D, Tibblin G, Wilhelmsen L. Smoking and myocardial infarction. Lancet 1975; 1: 415-20.
20. Auerbach O, Carter HW, Garfinkel L, Hammond EC. Cigarette smoking and coronary heart disease, a macroscopic and microscopic study. Chest 1976; 70: 697-705.
21. Glantz SA, Parmley WW. Passive smoking and heart disease. JAMA 1995; 273-1047-53.
22. Wells AJ. Passive smoking as a cause of heart disease. J Am Coll Cardiol 1994; 24: 546-54.
23. Leone A, Giannini D, Bellotto C, Balbarini A. Passive Smoking and Coronary heart disease. Curr Vasc Pharmacol 2004; 2: 175-82.
24. Byrd JC. Environmental tobacco smoke. Medical and legal issues. Med Clin North America 1992; 76: 377-97.
25. Imaizumi T, Satoh K, Yoshida H, Kawamura Y, Hiramoto M, Takamatsu S. Effect of cigarette smoking on the levels of platelet-activating factor-like lipid(s) in plasma lipoproteins. Atherosclerosis 1991; 87: 47-55.
26. Becker C, Dubin T. Activation of factor XII glicoprotein by tobacco. J Exp Med 1977; 146: 457-67.
27. Saba S, Mason R. Some effects of nicotine on platelets. Thromb Res 1975; 7: 819-24.
28. FitzGerald GA, Oates JA, Novak J. Cigarette smoking and hemostatic function. Am Heart J 1988; 115: 267-71.
29. Handin RI. Physiology of coagulation: The platelet. In: Nathan DG, Oski FA Eds, Hematology of infancy and childhood, 3d ed., Philadelphia Saunders 1987; 1271-92.
30. Schmidt A. Pflugers Archives 1872; 6: 445 (Quoted by Howell 1935).
31. Howell WH. Theories of blood coagulation. Physiol Rev 1935; 15: 435-70.
32. Mcfarlane RG. An enzyme cascade in the blood clotting mechanism and its function as a biochemical amplifier. Nature 1964; 202: 498-9.
33. Davie EW, Ratnoff ED. Waterfall sequence for intensive blood clotting. Science 1964; 145: 1310-2.
34. Rewak SD, Cochrane CG, Bouma BN, Griffin JH. Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma. J Exp Med 1978; 147: 719-29.
35. Hathaway WE, Belhanson LP, Hathaway HS. Evidence for a new thromboplastin factor. Case report, coagulation studies and physicochemical studies. Blood 1965; 26: 521-32.
36. Wuepper KD. Biochemistry and biology of components of the plasma kininforming system. In: Lepow MH, Ward PA Eds, Inflammation: mechanisms and control, Academic, New York 1972; 93 -117.
37. Peto R, Lopez AD, Boreham J, Thun M, Heath C. Mortality from smoking in developed countries: 1950-2000. Oxford: Oxford University Press 1994.
38. Wald NJ, Hackshaw AK. Cigarette smoking: An epidemiological overview. Br Med Bull 1996; 52: 3-11.
39. Leone A. Biochemical markers of cardiovascular damage from tobacco smoke. Curr Pharm Design 2005; 11: 2199-208.
40. Schulte MA, Waller BF, Hull MT, Pless JE. Origin of the left anterior descending artery from the right aortic sinus with intramyocardial tunneling to the left side of the heart via the ventricular septum: A case against clinical and morphologic significance of myocardial bridging. Am Heart J 1985; 110: 499-501.
41. Spach MS, Howell DA, Harris JS. Myocardial infarction and multiple thrombosis in a child with primary thrombocytosis. Pediatrics 1963; 31: 268-76.
42. Astrup P. The arterial wall in atherogenesis. In: Cavallero C Ed, Atherogenesis, Padua, Piccin Medical Book 1965; 77-92.
43. Aird WC. Hemostasis and irreducible complexity. J Thromb Haemost 2003; 1: 227-30.
44. ten Cate H, Aird WC. Lessons from venous thrombosis and disseminated intravascular coagulation: A synthesis of pathophysiological mechanisms of pro-thrombotic states. In: TenCate H, Levi M Eds, Molecular mechanisms of disseminated intravascular coagulation, Landes Bioscience Publisher, Texas; 2003.
45. Ross R. Atherosclerosis: An inflammation disease. N Engl J Med 1999; 340: 115-26.
46. Celermajer DS, Adams MR, Clarkson P, Robinson J, McRedie R, Donald A, et al. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N Engl J Med 1996; 334: 150-4.
47. Pittilo RM, Mackie IJ, Rowles PM, Machine SJ, Woolf N. Effects of cigarette smoking on the ultrastructure of rat thoracic aorta, and its ability to produce prostacyclin. Thromb Haemost 1982; 48: 173-6.
48. Davis J, Shelton L, Watanabe I, Arnold J. Passive smoking affects endothelium and platelets. Arch Intern Med 1989; 149: 386-9.
49. Sinzinger H, Kefalides A. Passive smoking severely decreases platelet sensitivity to antiaggregatory prostaglandins. Lancet 1982; 2: 392-3
50. Burghuber O, Punzengruber C, Sinzinger H, Haber P, Silberbauer K. Platelet sensitivity to prostacyclin in smokers and non-smokers. Chest 1986; 90: 34-8.
51. Martin JF, Bath PM, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet 1991; 338: 1409-11.
52. Stone MC, Thorpe JM. Plasma-fibrinogen- a major coronary risk factor. JR Coll Gen Pract 1985; 35: 565-9.
53. Taddei S, Ghiadoni L, Virdis A, Versari D, Salvetti A. Mechanisms of endothelial dysfunction: Clinical significance and preventive non-pharmacological therapeutic strategies. Curr Pharm Design 2003; 9: 2385-402.
54. Lusis AJ. Atherosclerosis. Nature 2000; 407: 233-41.
55. Libby P, Simon DI. Inflammation and thrombosis: The clot thickens. Circulation 2001; 103: 1718-20.
56. Prerovsky I, Hladovek J. Suppression of the desquamating effect of smoking on the human endothelium by hydroxyethylrutosides. Blood Vessels 1979; 16: 239-40.
57. Miyaura S, Eguchi H, Johnson JM. Effect of a cigarette smoke extract on the metabolism of the proinflammatory autacoid, platelet-activating factor. Circ Res 1992; 70: 341-7.
58. Moreno PR, Purushothaman KR, Fuster V, Echeverri D, Truszczynska H, Sharma SK, et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: Implications for plaque vulnerability. Circulation 2004; 110: 2032-8.
59. Luscher TF, Creager MA, Beckman JA, Cosentino F. Diabetes and vascular disease: Pathophysiology, clinical consequences, and medical therapy. Circulation 2003; 108: 1655-61.
60. Kario K, Matsuo T, Kobayashi H. Which factors affect high D-dimer levels in the elderly? Thromb Res 1991; 62: 501-8.
61. Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK. Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Atherosclerosis risk in Communities Study. Circulation 1995; 91: 284-90.
62. Lassila R, Peltonen S, Lepantalo M, Saarinen O, Kauhanen P, Manninen V. Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin. Arterioscler Thromb 1993; 13: 1738-42.
63. Herren T, Stricker H, Haeberli A, Do DD, Straub PW. Fibrin formation and degradation in patients with atherosclerotic disease. Circulation 1994; 90: 2679-86.
64. Smith FB, Rumley A, Lee AJ, Leng GC, Fowkes FG, Lowe GD. Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants. Br J Haematol 1998; 100: 758-63.
65. Hill D, Larcombe D, Refshauge J. Smoking and impairment of performance. Med J Aust 1978; 2: 60-3.
66. Anderson RF, Allensworth DC, DeGroot WJ. Myocardial toxicity from carbon monoxide poisoning: Ann Int Med 1967; 1172-82.
67. Marius-Nunez AL. Myocardial infarction with normal coronary arteries after acute exposure to carbon monoxide. Chest 1990; 97: 491-4.
68. Gvozdjakova A, Buda V, Sany L, Kurcharska J, Kruty F, Bozek P, et al. Smoke cardiomyopathy: Disturbance of oxidative processes in myocardial mitochondria. Cardiovasc Res 1984; 18: 229-32.
69. Thomsen HK, Kjeldsen K. Threshold limit for carbon monoxide-induced myocardial damage. Arch Environ Health 1974; 29: 73-8.
70. Lough J. Cardiomyopathy produced by cigarette smoke. Ultrastructural observations in guinea pig. Arch Pathol Lab Med 1978; 102: 377-80.
71. Kjeldsen K, Thomsen HK, Astrup P. Effects of carbon monoxide on myocardium. Ultrastructural changes in rabbits after moderate, chronic exposure. Circ Res 1974; 34: 339-48.
72. Leone A, Bertanelli F, Mori L, Fabiano P, Battaglia A. Features of ischaemic cardiac pathology resulting from cigarette smoking. J Smoking Related Dis 1994; 5: 109-14.
73. Leone A, Lopez M. Myocardial infarction and coronary damage in the smokers: Histopathologic features. XII Inter-American Congress of Cardiology, Vancouver, Canada, 1985; 13 Abstract.
74. Winniford MD, Jansen DE, Reynolds JA, Apprill P, Black WH, Hillis LD. Cigarette smoking-induced coronary vasoconstriction in atherosclerotic coronary artery disease and prevention by calcium antagonists and nitroglycerin. Am J Cardiol 1987; 59: 203-7.
75. Talks SJ, Chong NH, Gibson JM, Dodson PM. Fibrinogen, cholesterol and smoking as risk factors for non-arteritic anterior ischaemic optic neuropathy. Eye 1995; 9: 85-8.
76. Prentice RC, Carrol R, Scanlon PJ, Thomas JXJ. Recent exposure to cigarette smoke increases myocardial infarct size. J Am Coll Cardiol 1989; 13: 124A (Abstract).
77. Quillen JE, Rossen JD, Oskarsson HJ, Minor RLJ, Lopez AG, Winniford MD. Acute effect of cigarette smoking on the coronary circulation: constriction of epicardial and resistance vessels. J Am Coll Cardiol 1993; 22: 642-7.
78. Health or Smoking. Follow-up Report of the Royal College of Physicians. Pitman Publishing, London 1983.
79. Tsiara S, Elisaf M, Mikhailidis DP. Influence of smoking on predictors of vascular disease. Angiology 2003; 54: 507-30.
80. Cooper J, Douglas AS. Fibrinogen level as a predictor of mortality in survivors of myocardial infarction. Fibrinolysis 1991; 5: 105-8.
81. Resch KL, Ernst E, Matai A, Paulsen HF. Fibrinogen and viscosity as risk factors for subsequent cardiovascuar events in stroke survivors. Ann Intern Med 1992; 117: 371-5.
82. Zhu B, Parmley WW. Hemodinamic and vascular effects of active and passive smoking. Am Heart J 1995; 130: 1270-75.
83. Klein LW, Pichard AD, Holt J, Smith H, Gorlin R, Teichholz LE. Effects of chronic tobacco smoking on coronary circulation. J Am Coll Cardiol 1983; 1: 421-6.
84. Pohjola S, Siltanen P, Romo M. Five-year survival of 728 patients after acute myocardial infarction. Br Heart J 1980; 43: 176-83.
85. Daly LE, Mulkahy R, Graham IM, Hickey N. Long-term effect on mortality of stopping smoking after unstable angina and myocardial infarction. BMJ 1983; 287: 324-6.
86. Jenkins CD, Zyzansky SJ, Rosenman RH. Risk of a new myocardial infarction in middleaged men with manifest coronary heart disease. Circulation 1976; 53: 342-7.
87. Vliestra RE, Kronmal RA, Oberman A. Stopping smoking improves survival in patients with angiographically-proven coronary artery disease. Am J Cardiol 1982; 49: 984A.
88. Szilagyi ED, Elliot JP Jr, Smith RF, Reddy DJ, McPharlin M. A thirty-year survey of the reconstructive surgical treatment of aortoiliac occlusive disease. J Vasc Surg 1986; 3: 421-36.
89. Hertzer NR, Beven EG, Young JR, O'Hara PJ, Ruschhaupt WF III, Graor RA, et al. Coronary artery disease in peripheral vascular patients: A classification of 1000 coronary angiograms and results of surgical management. Ann Surg 1984; 199: 223-33.
90. Consensus: Estrogen use and postmenopausal women. National Institutes of Health Consensus Development Conference Summary1979; 2: 8. A consensus on the state of the heart as relates to risks and benefits.
91. Mishell DR Jr. Contraception: In: De Groot LJ. Endocrinology, Vol 3, Grune_Stratton, New York 1979; 1435-50.
92. Leone A, Lopez M. Role du tabac et de la contraception orale dans l'infarctus du myocarde de la femme. Description d;un cas. Pathologica 1984; 76: 493-8.
93. Leone A, Lopez M. Oral contraception, ovarian disorders and tobacco in myocardial infarction of woman. Pathologica 1986: 78: 237-42.
94. Rosemberg L, Slone D, Shapiro S, Kaufman DW, Stolley PD, Miettinen OS. Noncontraceptive estrogens and myocardial infarction in young women. JAMA 1980; 244: 339-42.
95. Ross RK, Paganini-Hill A, Mack TM, Arthur M, Henderson BE. Menopausal oestrogen therapy and protection from death from ischaemic heart disease. Lancet 1981; 1: 858-60.
96. Chastre J. Infarctus du myocarde: Role du tabac et des contraceptives oraux. Nouvelle Press Med 1977; 12: 1005.
97. Vessey MP, McPherson K, Yeates D. Mortality in oral contraceptive users. Lancet 1981; I: 549-50.
98. Kurth T, Kase CS, Berger K, Graziano JM, Cook NR, Buring JE. Smoking and risk of hemorrhagic stroke in women. Stroke 2003; 34: 2792-5.
99. Hurn PD, Brass LM. Estrogen and stroke: A balanced analysis. Stroke 2003; 34: 338-41.
100. Higashi Y, Sanada M, Sasaki S, Nakagawa K, Goto C, Matsuura H, et al. Effect of estrogen replacement therapy on endothelial function in peripheral resistance arteries in normotensive and hypertensive postmenopausal women. Hypertension 2001; 37: 651-7.
101. Stier CT Jr, Chander PN, Rosenfeld L, Powers CA. Estrogen promotes microvascular pathology in female stroke-prone spontaneously hypertensive rats. Am J Physiol Endocrinol Metab 2003; 285: E 232-9.
102. Tsuda K, Kinoshita-Shimamoto Y, Mabuchi Y, Nishio I. Hormone replacement therapy improves membrane fluidity of erythrocytes in postmenopausal women: An electron paramagnetic resonance investigation. Am J Hypertens 2003; 16: 502-7.
103. Wassertheil-Smoller S, Hendrik SL, Limacher M, Heiss G, Kooperberg C, Baird A, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: TheAWomen's Health Initiative: a randomized trial. JAMA 2003; 289: 2673-84.
104. Rexrode KM, Manson JE, Lee IM, Ridker PM, Sluss PM, Cook NR, et al. Sex hormone levels and risk of cardiovascular events in postmenopausal women. Circulation 2003; 108: 1688-93.
105. Humphrey LL, Chan BKS, Sox Jr. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 2002; 137(4): 273-84.
106. Miller J, Chan BKS, Nelson HD. Hormone replacement therapy and risk of venous thromboembolism: A systematic review and meta-analysis. Ann Intern Med 2002; 136(3): 680-90.
107. Wilson PW, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study. N Engl J Med 1985; 313(17): 1038-43.
108. Petitti DB, Perlman JA, Sidney S. Non contraceptive estrogens and mortality: Long-term follow-up of women in the Walnut Creek Study. Obstet Gynecol 1987; 70: 289-93.
109. Mueck AO, Seeger H. Smoking, estradiol metabolism, and hormone replacement therapy. Arzneimittelforschung 2003; 53: 1-11.
110. Tsuda K, Nishio I. A selective estrogen receptor modulator, tamoxifen, and membrane fluidity of erythrocytes in normotensive and hypertensive postmenopausal women: An Electron Paramagnetic Resonance investigation. Am J Hypertens 2005; 18: 1067-76.
111. AHA: Heart Disease and Stroke Statistics: 2004 Update. www.Americanheart.org 2004.
112. Hachinski V. Stroke prevention. In 23rd Congress of the International Society of Internal Medicine, Aquino AV, Piedad FF, and Sulit YQM Eds, Monduzzi Editore, Bologna, Italy (International Proceedings Division), 1996; 257-61.
113. Jaumdally JR, Lip GY, Varma C. Traditional risk factors for coronary atherosclerosis in Indo Asians: The need for a reappraisal. Curr Pharm Des 2006; 12(13): 1611-21.
114. Leone A. Biochemical markers of cardiovascular damage from tobacco smoke. Curr Pharm Des 2005; 11(17): 2199-208.
115. Ruano-Ravina A, Figueiras A, Freire-Garabal M, Barros-Dios JM. Antioxidant vitamins and risk of lung cancer. Curr Pharm Des 2006; 12(5): 599-613.